Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FluorThanatrace PET Imaging in Cancer
NCT02469129Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2015
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]FluorThanatrace in cancer (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Whole body effective dose and doses to critical organs at 1 day. Started Mar 2015; status: active, not recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02469129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469129.